July 25, 2022 10:36 AM EDTUpdated 10:49 AM
Pharma
FDA+

Medexus re­sub­mits NDA as it still looks to re­pur­pose a decades-old drug

Tyler Patchen

News Reporter

The Ger­man drug­mak­er medac’s US sub­sidiary is hop­ing the sec­ond time is the charm for the com­pa­ny, as it is of­fi­cial­ly ask­ing the FDA once …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times